BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fontes-Sousa M, Magalhães H, Oliveira A, Carneiro F, Dos Reis FP, Madeira PS, Meireles S. Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? Adv Ther 2022;39:1107-25. [PMID: 35025061 DOI: 10.1007/s12325-021-02007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Franczyk B, Rysz J, Ławiński J, Ciałkowska-Rysz A, Gluba-Brzózka A. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. Biomedicines 2023;11. [PMID: 36672689 DOI: 10.3390/biomedicines11010181] [Reference Citation Analysis]
2 Grammatikaki S, Katifelis H, Farooqi AA, Stravodimos K, Karamouzis MV, Souliotis K, Varvaras D, Gazouli M. An Overview of Epigenetics in Clear Cell Renal Cell Carcinoma. In Vivo 2023;37:1-10. [PMID: 36593023 DOI: 10.21873/invivo.13049] [Reference Citation Analysis]
3 Korkmaz M, Eryılmaz M, Koçak M, Er M, Hendem E, Demirkıran A, Araz M, Karaağaç M, Artaç M. Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy? J Can Res Ther 2023;0:0. [DOI: 10.4103/jcrt.jcrt_898_22] [Reference Citation Analysis]
4 Bialek J, Yankulov S, Kawan F, Fornara P, Theil G. Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC). Biomedicines 2022;10. [PMID: 36552000 DOI: 10.3390/biomedicines10123244] [Reference Citation Analysis]
5 Lu C, Wang Y, Nie L, Chen L, Li M, Qing H, Li S, Wu S, Wang Z. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma. Front Immunol 2022;13:934243. [DOI: 10.3389/fimmu.2022.934243] [Reference Citation Analysis]
6 Rosellini M, Marchetti A, Tassinari E, Nuvola G, Rizzo A, Santoni M, Mollica V, Massari F. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development 2022;7:131-149. [DOI: 10.1080/23808993.2022.2156786] [Reference Citation Analysis]